D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$1.2B |
| 2 |
Boston Scientific
BSX
|
+$1.05B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$934M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$924M |
| 5 |
JPMorgan Chase
JPM
|
+$922M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.2B |
| 2 |
NVIDIA
NVDA
|
+$1.58B |
| 3 |
Palantir
PLTR
|
+$901M |
| 4 |
Netflix
NFLX
|
+$883M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$805M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 30.42% |
| 2 | Technology | 18.55% |
| 3 | Consumer Discretionary | 8.97% |
| 4 | Financials | 8.5% |
| 5 | Healthcare | 8.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4126
Resources Connection
RGP
$94.7M
| $179K | ﹤0.01% |
48,034
-162,910
| -77% | -$667K |
2023 Q1
12 quarters
|
|
4127
Lexeo Therapeutics
LXEO
$225M
| $175K | ﹤0.01% |
30,477
-449,728
| -94% | -$3.19M |
2025 Q3
2 quarters
|
|
4128
PUT
Alight
ALIT
$243M
| $175K | ﹤0.01% |
15,000
+10,000
| +200% | +$238K |
2025 Q4
1 quarter
|
|
4129
Titan America SA
TTAM
$2.42B
| $174K | ﹤0.01% |
+11,584
| New | +$198K |
2026 Q1
0 quarters
|
|
4130
BRT Apartments
BRT
$251M
| $172K | ﹤0.01% |
+12,864
| New | +$187K |
2026 Q1
0 quarters
|
|
4131
Kingsoft Cloud Holdings
KC
$2.79B
| $171K | ﹤0.01% |
12,828
-348,772
| -96% | -$4.56M |
2024 Q4
5 quarters
|
|
4132
Ironwood Pharmaceuticals
IRWD
$593M
| $168K | ﹤0.01% |
47,938
-69,508
| -59% | -$285K |
2013 Q2
51 quarters
|
|
4133
Ginkgo Bioworks
DNA
$792M
| $167K | ﹤0.01% |
27,169
-6,603
| -20% | -$54.9K |
2025 Q4
1 quarter
|
|
4134
PUT
AGNC Investment
AGNC
$10.2B
| $166K | ﹤0.01% |
+16,600
| New | +$184K |
2026 Q1
0 quarters
|
|
4135
AgomAb Therapeutics NV
AGMB
$434M
| $161K | ﹤0.01% |
+15,326
| New | +$217K |
2026 Q1
0 quarters
|
|
4136
Clover Health Investments
CLOV
$2.55B
| $160K | ﹤0.01% |
91,011
-191,679
| -68% | -$416K |
2025 Q2
3 quarters
|
|
4137
Schrodinger
SDGR
$1.94B
| $160K | ﹤0.01% |
+14,041
| New | +$194K |
2026 Q1
0 quarters
|
|
4138
Independence Realty Trust
IRT
$3.5B
| $159K | ﹤0.01% |
+10,645
| New | +$175K |
2026 Q1
0 quarters
|
|
4139
Blueport Acquisition Ltd
BPAC
$75.5M
| $156K | ﹤0.01% |
+15,610
| New | +$156K |
2026 Q1
0 quarters
|
|
4140
BCB Bancorp
BCBP
$251M
| $154K | ﹤0.01% |
17,174
-18,421
| -52% | -$151K |
2024 Q2
7 quarters
|
|
4141
Similarweb
SMWB
$767M
| $153K | ﹤0.01% |
58,552
+30,176
| +106% | +$126K |
2023 Q2
11 quarters
|
|
4142
Franklin Street Properties
FSP
$41.2M
| $151K | ﹤0.01% |
227,035
-584,654
| -72% | -$452K |
2020 Q2
23 quarters
|
|
4143
Perimeter Acquisition Corp I Warrant
PMTRW
$7.25M
| $150K | ﹤0.01% |
250,000
| – | – |
2025 Q2
3 quarters
|
|
4144
Archimedes Tech SPAC Partners II Co Warrant
ATIIW
$13.2M
| $147K | ﹤0.01% |
287,500
| – | – |
2025 Q2
3 quarters
|
|
4145
Forrester Research
FORR
$226M
| $146K | ﹤0.01% |
25,811
-96,513
| -79% | -$660K |
2023 Q4
9 quarters
|
|
4146
Adamas Trust
ADAM
$684M
| $145K | ﹤0.01% |
+19,732
| New | +$157K |
2026 Q1
0 quarters
|
|
4147
Verastem
VSTM
$675M
| $141K | ﹤0.01% |
26,659
-312,194
| -92% | -$1.93M |
2025 Q3
2 quarters
|
|
4148
Recursion Pharmaceuticals
RXRX
$2.05B
| $141K | ﹤0.01% |
46,008
-43,536
| -49% | -$168K |
2025 Q4
1 quarter
|
|
4149
Lumexa Imaging Holdings
LMRI
$1.02B
| $141K | ﹤0.01% |
16,418
-183,582
| -92% | -$2.52M |
2025 Q4
1 quarter
|
|
4150
MaxCyte
MXCT
$99.5M
| $141K | ﹤0.01% |
200,505
-463,451
| -70% | -$433K |
2024 Q3
6 quarters
|
|
Similar funds
D.E. Shaw & Co's Q1 2026 Portfolio in Review
As of Q1 2026, D.E. Shaw & Co held 5,226 positions worth $166B, down 8.8% from $182B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
D.E. Shaw & Co withdrew a net $5.92B in Q1 2026, closing 756 positions and reducing 1,922 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $805M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 30% of assets, down from 36% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, D.E. Shaw & Co opened a new position in Venture Global Inc worth $211M.
- D.E. Shaw & Co's largest Q1 2026 buy was Venture Global Inc: 13,410,074 shares worth $211M.
- D.E. Shaw & Co added most to Broadcom in Q1 2026, an estimated $1.2B increase.
- D.E. Shaw & Co's biggest Q1 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $3.2B.
- D.E. Shaw & Co fully exited iShares Core S&P 500 ETF in Q1 2026, selling an estimated $805M.
- D.E. Shaw & Co's ten largest holdings make up 11% of its $166B portfolio in Q1 2026.
- D.E. Shaw & Co opened 685 new positions and closed 756 in Q1 2026.
- D.E. Shaw & Co's portfolio value fell 8.8% quarter-over-quarter to $166B.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.